Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers by Sanchez-Garcia F et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Sanchez-Garcia F, Villagrasa P, Matsui J, Kotliar D, Castro V, Akavia UD, Chen 
BJ, Saucedo-Cuevas L, Rodriguez-Barrueco R,  
Llobet-Navas D, Silva JM, Pe'er D.  
Integration of Genomic Data Enables Selective Discovery of  
Breast Cancer Drivers.  
Cell 2014, 159(6), 1461-1475. 
 
 
Copyright: 
© 2014. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
DOI link to article: 
http://dx.doi.org/10.1016/j.cell.2014.10.048  
Date deposited:   
02/09/2016 
Integration of Genomic Data Enables Selective Discovery of 
Breast Cancer Drivers
Félix Sanchez-Garcia1,2,*, Patricia Villagrasa3,*, Junji Matsui3, Dylan Kotliar1, Verónica 
Castro3, Uri-David Akavia1,4, Bo-Juen Chen1, Laura Saucedo-Cuevas3, Ruth Rodriguez 
Barrueco3, David Llobet-Navas3, Jose M. Silva3,5,#, and Dana Pe’er1,5,#
1Department of Biological Sciences and Department of Systems Biology, Columbia University, 
New York, NY 10027
2Department of Computer Science, Columbia University, New York, NY 10027
3Icahn School of Medicine at Mount Sinai, The Mount Sinai Hospital, NY 10029
Abstract
Identifying driver genes in cancer remains a crucial bottleneck in therapeutic development and 
basic understanding of the disease. We developed Helios, a novel algorithm that integrates 
genomic data from primary tumors with data from functional RNAi screens to pinpoint driver 
genes within large recurrently amplified regions of DNA. Applying Helios to breast cancer data 
identified a set of candidate drivers highly enriched with known drivers (p-value < e−14). 9/10 top 
scoring Helios genes are known drivers of breast cancer and in vitro validation of 12 novel 
candidates predicted by Helios found 10 conferred enhanced anchorage independent growth, 
demonstrating Helios’s exquisite sensitivity and specificity. We extensively characterized RSF-1, 
a driver identified by Helios whose amplification correlates with poor prognosis, and found 
increased tumorigenesis and metastasis in mouse models. We have demonstrated a powerful 
approach for identifying novel driver genes and how it can yield important insights into cancer.
Introduction
Cancer genome data collected by projects such as the TCGA or ICGC is defining the 
landscape of genetic alterations that underlie cancer. Tumor cells may harbor thousands of 
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genetic lesions including point mutations, somatic copy-number alterations, and 
translocations that localize to hundreds or even thousands of genes. However, most affected 
genes are so-called passengers and their alteration does not confer any type of advantage to 
tumors (Vogelstein et al., 2013). A pivotal challenge in cancer genomics is to identify the 
small subset of altered genes (so-called drivers) that directly contribute to tumor fitness and 
progression.
Exome sequencing studies helped identify driver genes (Curtis et al., 2012; Stephens et al., 
2012), however the majority of point mutations display low population frequencies, with 
only a handful altered in greater than 5% of patients (Stephens et al., 2012). In breast cancer, 
only 6 genes have point mutations in >5% of samples, and of these, only PIK3CA (36% 
frequency) is currently targeted therapeutically (TCGA, 2012). Instead, the most recurrent 
genetic lesions in breast cancer are somatic copy number alterations (SCNAs), often driven 
by inactivation of DNA repair genes such as BRCA1/2. Indeed, HER2, one of the most 
therapeutically targeted drivers in breast cancer, is primarily dysregulated by copy-number 
amplification.
The ability to discern drivers from copy-number alteration promises to dramatically expand 
the set of therapeutic targets in this disease. However, this potential is crucially hindered by 
the difficulty of driver discovery (Yuan et al., 2012). The crux of the difficulty is that in all 
but a few instances, these lesions contain dozens of genes and no previously characterized 
drivers (Albertson et al., 2003). A recent study analyzing multiple tumor types reported that 
over 70% of 140 recurrently altered regions did not contain a known oncogene or tumor 
suppressor (Zack et al., 2013). As a result, most recent driver discovery efforts have focused 
on point mutations, which directly indicate the target genes by virtue of their precise 
location (Kandoth et al., 2013; Lohr et al., 2012; Wong et al., 2011), and less progress has 
been made with respect to SCNAs. However, the increased frequency of recurring SCNAs 
relative to mutations (87 SCNA regions vs. 6 mutated genes with >5% population 
frequency) (Figure 1A) highlights the need for methods to pinpoint drivers within these 
regions.
Genome-wide pooled-RNAi screening is an alternative approach to driver gene discovery. 
In these studies, a shRNA library is transduced into cancer cell lines and the growth effect of 
each individual gene knock-down is assessed for each cell line (Cheung et al., 2011; 
Marcotte et al., 2012; Silva et al., 2008). While such studies can provide gene-level 
resolution, they are currently limited by the high degree of noise, the potential for off-target 
effects of shRNAs and by the artificiality of the in-vitro screening system (Kaelin, 2012). 
Moreover, cell-lines are not fully representative of primary tumor biology as these lack 
tissue structure and microenvironment, which are key to cellular behavior (Bissell and 
Hines, 2011).
Given the largely orthogonal strengths and weaknesses of descriptive analysis of primary 
cancer genomes and in-vitro genome-wide functional screening, we hypothesized that 
integrating the two data types into a single approach would result in increased resolution and 
accuracy for driver gene discovery. Therefore, we developed Helios (Figure 1B), a novel 
algorithm that incorporates primary tumor SCNA, point mutation, gene expression, and 
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RNAi screens into a single candidate driver score. Helios runs in two steps, first identifying 
regions of focal SCNAs and then identifying driver genes within each region by integrating 
functional screens and other data using a Bayesian transfer-learning framework.
Helios displayed a remarkable capacity to pinpoint bona fide cancer drivers when the 
algorithm was used to analyze the SCNA landscape of breast cancer. In a systematic 
evaluation of Helios’s performance, we selected 12 novel driver candidates identified by 
Helios, based on their frequency of occurrence, for experimental investigation. We found 
10/12 candidate genes induced increased anchorage independent growth when over-
expressed in vitro. Thus, Helios demonstrated an unprecedented sensitivity and specificity in 
identifying genes that promote oncogenic capabilities. Helios doubled the number of SCNA 
drivers identified in breast cancer and substantially increased our understanding of the breast 
cancer SCNA landscape.
Results
ISAR expands the list of significantly amplified regions in breast cancer
The first step for identifying SCNA-drivers is identification of significantly altered regions. 
There are multiple algorithms that successfully perform this task (Mermel et al., 2011; 
Walter et al., 2011), GISTIC2 being the most widely used among these. We noted a number 
of oncogenes (e.g. BCL2) that were not detected as falling within a significantly altered 
region by GISTIC2 in the TCGA breast cancer data (TCGA, 2012). By visual inspection of 
chromosome 18, we noted that while BCL2 does not appear significantly amplified based on 
its absolute copy-level, its copy-number is nevertheless significantly higher than the 
adjacent chromosomal regions (Supplementary Figure 1). Most SCNA detection algorithms, 
including GISTIC2, compute a null distribution across the entire genome to estimate the 
significance of alterations. However, the alteration rate can strongly differ across different 
genomic regions, due to features such as DNA secondary structure and DNA 
hypomethylation (De and Michor 2011).
Therefore, we developed ISAR (Identification of Significantly Altered Regions), an 
algorithm that accounts for local differences in SCNA rate due to these and other forces. By 
computing the significance locally, the algorithm is capable of identifying both global 
alteration events, as well as subtle events, such as a focal amplification within largely 
deleted regions, that would be missed if the background distribution for the whole genome 
were employed (See Methods). We applied ISAR to 785 breast cancer samples (TCGA, 
2012) and identified 83 significantly amplified regions (see Supplementary table 1), 
compared to the 30 regions originally reported by the TCGA consortium. ISAR captures all 
significant regions captured by GISTIC2 and many additional regions. Among the new 
regions we find many bona-fide or likely oncogenes, including MYB, BCL2, CDK4, ESR1, 
FGFR2, FGFR3 and FGFR4. Identified regions contained an average of 14 genes resulting 
in a total of 1226 significantly amplified genes across all 83 regions.
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Helios: An Integrative Approach to Pinpoint Drivers
Helios seeks to exploit additional properties —e.g. recurrent domain-specific point 
mutations or depletion in a lethality shRNA screen—to implicate likely driver genes 
targeted by the SCNA. Helios considers the entire significantly altered region, but prioritizes 
the genes within this region by incorporating cues from additional genetic and genomic data 
to estimate the probability that each is a driver (Figure 2A). It is a statistically rigorous 
framework for combining multiple signals that might lack power individually into a single 
score for the likelihood that each gene’s amplification specifically increases tumor fitness. 
Here, we integrate features derived from exome-sequencing, shRNA screening and gene-
expression, but due to the flexibility of our framework, these could readily be removed, 
modified or extended for subsequent studies.
Helios uses a set of features to classify genes as either drivers or passengers, based on 
inference within a hierarchical Bayesian mixture model (see Methods, Supplementary 
Figure 2). Standard classification approaches rely on an initial list of examples—drivers and 
passengers—to train the model. Unfortunately, the list of known oncogenic drivers is 
relatively small and strongly biased towards kinases and extreme phenotypes that facilitate 
discovery. Instead, Helios begins with the assumption that a driver gene is more likely to be 
near the most frequently amplified segment (defined as peak) of the ISAR region. This is 
used to initialize the algorithm by providing an estimated list of drivers to start from. Helios 
then iterates between 2 stages until convergence:
1. Learning the parameters to distinguish passengers and drivers on the basis of their 
SCNA profile and on the additional genomic data
2. Re-computing the probability that each gene is a driver using the parameters 
determined in step 1
Helios uses a transfer learning approach (Widmer and Rätsch, 2011) whereby drivers with 
clearer signal (e.g. at the peak of their region) are used to extract informative features to 
improve performance in cases with less obvious signal. Helios automatically learns the 
weights of features directly from the data by leveraging information among features. In each 
iteration, Helios learns a better classification of drivers and passengers, which in turn is used 
to learn better parameters, until convergence (see Supplementary Methods). Helios utilizes a 
mixture of two copy-number distributions– one for drivers and one for passengers, thus 
avoiding the problematic selection of a hard threshold for defining aberrant regions (Figure 
2B). Additionally, Helios permits final models where more than one gene in a region is 
identified as a likely driver, or where no probable driver genes are identified.
Finally, Helios can readily incorporate additional features, including complex features 
generated by combinations of multiple data sources. It automatically learns the contribution 
and importance of each feature directly from the data, making it easily extendable and 
adaptable to other cancer types. For example, here, we integrate data from functional screens 
based on the concept of oncogene addiction (Weinstein and Joe, 2008) by deriving a 
composite statistic reflecting the extent to which shRNA-depletion in a genome-wide screen 
correlated with over-expression of the gene at baseline. A similar idea has recently been 
used to discover the novel oncogene HNF1B (Shao, Tsherniak et al. 2013). Our oncogene 
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addiction score allows for both linear and non-linear relations between gene expression and 
lethality (See Figure 2B–D, Methods). This ability to combine multiple weaker pieces of 
evidence from heterogeneous data types into a single score enables Helios to effectively 
pinpoint the driver gene from within the recurrently altered region.
Helios identifies candidate drivers of breast cancer
We used Helios to integrate TCGA data from 785 primary breast cancer tumors, including 
DNA copy number, gene expression and sequence mutations (TCGA, 2012), with data from 
27 breast cancer cell lines including gene expression, copy number and shRNA depletion in 
a genome-wide shRNA screen (Barretina et al., 2012; Marcotte et al., 2012).
Using stringent criteria, we defined 64 candidate drivers by selecting only the top gene in 
each region and applying a threshold of Helios score > 0.5 (see Supplementary Table 2). 
Some significant SCNA regions did not contain a high scoring protein-coding gene; these 
amplifications potentially target non-coding RNA or other genomic features. For example, 
all protein-coding genes were low-scoring in an amplified region containing the known 
oncomir mir21 (O’Day and Lal, 2010). While approximately 20% of the regions contained 
more than one high scoring gene, we limited our initial analysis to the highest scoring gene 
in each region.
To evaluate the sensitivity of our approach, we combined several publically available 
resources to create a comprehensive set of breast cancer oncogenes ((Beroukhim et al., 
2010; Consortium, 2013; Frankild and Jensen), (Supplementary methods)). Among the 10 
top scoring Helios genes, 9 were included in this set (FOXA1, PIK3CA, CCND1, CDK4, 
MYB, ERBB2, IGF1R, BCL2, ESR1), while only 5 of these appear in regions that are 
significant based on GISTIC2. Moreover, the entire list of 64 Helios candidates was 
significantly enriched for our compiled set of breast cancer drivers (16/64, p-value < 4e−15), 
a large improvement over the set of all genes in amplified regions identified by GISTIC2 
(17/452, p-value > e−3) (TCGA, 2012) (Figure 3A). The performance of the method was 
also compared against two other algorithms, GAIA (Morganella et al., 2011) and DiNAMIC 
(Walter et al., 2011), outperforming both of them (18/768, p-value > e−3 and 185/10651, p-
value > e−3 respectively). This demonstrates the significant improvement of our integrative 
approach over the state of the art.
Helios’s integration across multiple data sources is key to its ability to be both specific and 
sensitive. Sequence mutations are gene-specific, but only few drivers harbor such mutations 
recurrently. SCNAs typically cover a large number of genes, making it hard to identify the 
target of the amplification based on copy number alone. For instance, CDK4 shares exactly 
the same copy number profile with its five closest neighbors, but the lethality displayed by 
CDK4 in the shRNA screen raises its Helios score (Figure 3B). More strikingly, BCL2 is 
only the sixth gene in its region in terms of copy number alteration frequency, but its 
dramatic oncogene addiction score raises its Helios score well above all others in the region 
(Figure 3C). In many cases (e.g. EGFR or ADAM15, Figure 3D–E), it is not any single 
feature, but a combination of features that identifies the top-scoring gene in the region. 
Figure 3F shows how Helios outperforms the simple use of the data sources independently 
to identify drivers. Even if all of the candidates obtained by each data source are joined 
Sanchez-Garcia et al. Page 5
Cell. Author manuscript; available in PMC 2015 December 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
together naively, Helios provides significantly better sensitivity (15 versus 9 detected driver 
genes) and specificity (hypergeometric enrichment p-value of driver genes 8.16E−14 versus 
4.72E−11).
Candidate selection for systematic in vitro validation of Helios-predicted genes
Helios is designed to rank genes within an amplified region based on their likely driver 
capacity. Contrary to most prior work that prioritized kinases for experimental validation, 
for an unbiased evaluation of Helios, we chose a systematic score driven approach to 
validation. To perform an unbiased and comprehensive assessment, over a wide range of 
Helios scores, we used the independent ISAR score > 5.5 to select regions and used Helios 
to pinpoint the most likely driver within each region. Thus we sought to assess how often 
could Helios pinpoint the correct driver for each of the 17 most frequently and significantly 
amplified regions.
In 7 of the 17 regions, the top Helios gene was a bona-fide breast cancer oncogene (ERBB2, 
CCND1, ZNF217, MYC, miR-21, FGFR2 and IGF1R) and these oncogenes scored well 
above the next best scoring gene. For example, MYC’s Helios score was 100 times greater 
than the 2nd best gene in the region (Figure 4, “Ratio-next” column). There was no known 
breast cancer oncogene present among 10 additional regions and therefore we decided to 
perform in vitro validation for the top scoring Helios genes in each of these regions. Since 
an amplified region can harbor more than one oncogene, we selected multiple genes if more 
than one was significantly scoring (4/10 regions). We failed to clone over-expression vectors 
for three genes, resulting in a final selection of 12 predicted oncogenes for validation. The 
selected genes encompassed a wide range of functional roles including chromatin 
remodeling, transcription factors, cell surface and cell adhesion proteins and metabolic 
enzymes.
One of the hallmarks of transformation that is commonly used to investigate putative 
epithelial oncogenes is the ability to promote attachment independent growth of a non-
transformed cell line (Hanahan and Weinberg, 2011). This capacity likely reflects the 
cumulative impact of multiple signals such as increased resistance to stress, increased 
cellular growth rates and changes in metabolism (Davison et al., 2013). As a result, many 
driver alterations in cancer may potentially impact attachment independent growth through 
multiple mechanisms. Therefore, we based our candidate validation strategy on assaying this 
phenotype.
Experimental in vitro validation confirms Helios-predicted genes
For each of the 12 candidate genes, we evaluated the ability of a clone of MCF-10A cells 
(human mammary epithelium) with intrinsic low attachment independent growth ability, 
(see methods) to form colonies in semi-solid media when the putative oncogene was 
experimentally upregulated. These cells were transduced with viral vectors over-expressing 
the putative driver and evaluated for growth in soft agar. CCND1 and MYC were used as 
positive controls, and for negative controls, we selected 5 genes from significantly amplified 
ISAR regions (ISAR > 5.5) that did not have a high Helios score (score < 0.3). The agar 
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assays for each gene was tested with a minimum of 6 replicates and statistical significance 
was evaluated by unpaired two-sample t-test between the 6 test and 6 control plates.
10/12 tested genes (C6ORF23, BEND3, YEATS4, RSF-1, PRKCZ, GNB1, ZNF652, NIT1, 
PVRL4 and TRPS1) were able to significantly increase MCF10A anchorage independent 
activity with a p-value of 0.005 or below (Figure 4). None of the negative controls 
demonstrated an increase in colony formation. This provides in vitro evidence that Helios is 
highly specific in identifying genes that provide a selective advantage for breast cancer cells. 
Note that a negative result for BRF2 (demonstrated to be an oncogene in lung cancer 
(Lockwood et al., 2010)) does not conclusively rule it out as a driver gene, since attachment 
independent growth is not the only hallmark of cancer and the assays were performed in a 
single genetic background.
Overall, Helios demonstrated unprecedented accuracy in identifying genes that promote 
oncogenic capabilities. Helios correctly scored 13/14 drivers at the top of their respected 
region (93%). Moreover, 10/12 empirically tested genes validated (83%), thus we identified 
9 new genes that promote tumorigenic capabilities in breast cancer (excluding PVRL4 
which was recently published (Pavlova et al., 2013)). Additionally, since the genes were 
selected based on the region’s significance, rather than their Helios score, a wide range of 
Helios scores were tested (between 0.36 to 0.79), increasing our confidence in the 
candidates identified in other regions. Based on this performance, we expanded our list of 
likely drivers based on Helios predictions with more permissive criteria (Supplementary 
Table 3).
Importantly, Helios identified multiple high scoring (likelihood>0.5) genes for over 20% of 
the regions. Indeed, we validated three regions with multiple genes and each gene 
independently induced colony formation in vitro (Figure 4, green boxes), indicating that an 
amplicon often targets more than one gene. In summary, while previously only 7/17 of the 
most frequently altered regions in breast cancer harbored a known oncogene, following our 
validation 14/17 regions can be assigned a driver with substantial confidence.
RSF-1 Promotes Colony Growth In Vitro
Among the 10 validated candidates, RSF-1 is an especially compelling putative driver 
because it is recurrently amplified in several cancers (Chen et al., 2011; Fang et al., 2011; Li 
et al., 2012; Liu et al., 2012; Shih Ie et al., 2005). Additionally, an amplicon containing 
RSF-1 was recently associated with a breast cancer subtype bearing one of the worst clinical 
prognoses (Curtis et al., 2012). Although high expression levels of RSF-1 has been 
associated with poor prognosis in several malignancies (Hu et al., 2012; Li et al., 2012; Liu 
et al., 2012; Sheu et al., 2013), its involvement in breast cancer pathogenesis has not yet 
been explicitly demonstrated. Therefore, we chose to follow-up our analysis of RSF-1 with 
further in-vitro and in-vivo experiments.
We selected four additional mammary epithelial cell lines non-amplified for RSF-1. The 
human MCF-10A-Triple Modified (a MCF-10A variant sensitized to transformation called 
here MCF-10A-TM (Pires et al., 2013)), MDA-MB-415 and MDA-MB-361; and the mouse 
Comma-ID (C-ID) (Campbell et al., 1988). We also selected one cell line (MDA-MB-453, 
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human) with amplified and over-expressed RSF-1 (Supplementary Figure 5A). 
Overexpression of RSF-1 in all non-amplified cell lines increased the ability to form 
colonies in semisolid media (Figure 5A). To assay RSF-1 oncogene addiction, we selected 
two doxycycline (Dox) inducible shRNA-miRs that efficiently silenced RSF-1 and assayed 
colony formation of the RSF-1 amplified MDA-MB-453 line. As expected, silencing of 
RSF-1 significantly reduced the number of colonies formed (Figure 5B). To demonstrate 
that the loss of tumorigenic potential is not an off-target effect, we restored RSF1 expression 
in these cells by overexpressing the RSF1 cDNA (Supplementary Figure 5C). Restoring 
RSF1 levels rescued the ability of MDA-MB-453 to form colonies in agar despite the 
expression of RSF1 shRNAs.
RSF-1 Promotes Growth in Xenograft Models
Next, we conducted experiments to assay RSF-1 in vivo. MCF-10A-TM and C-ID were 
orthotopically transplanted into the fat pad of immunocompromised (SCID) mice with and 
without prior transduction of an RSF-1 over-expression vector. We then tracked the 
development of tumors and compared growth between controls and those over-expressing 
RSF-1.
MCF-10A cells are not tumorigenic, and overexpression of RSF-1 did not transform them. 
While some transplanted MCF-10A-TM cells remained in the fat pad, these did not produce 
tumor. However MCF-10A-TM overexpressing RSF-1 was able to establish small primary 
tumor outgrowths (Figure 5C and Supplementary Figure 5B). C-ID overexpressing RSF-1 
cells generated palpable masses as early as 2 weeks after transplantation—significantly 
earlier than control mice, which lacked detectable tumor burden after 1 month. (P=0.0001) 
(Figure 5D and Supplementary Figure 5B).
Finally, we also transplanted RSF-1 amplified MDA-MB-453 cells and an MDA-MB-453 
variant bearing a doxycycline inducible RSF-1-ShRNA into the fat pad of SCID mice. As 
expected, in the absence of Dox all MDA-MB-453 variants generated tumors that grew at a 
comparable rate. However, supplementing the mice with Dox reduced the tumorigenic 
growth specifically in the tumors carrying the RSF-1 shRNA (Figure 5E). This data provides 
evidence that RSF-1 can contribute to tumor progression in vivo and that inhibition of RSF-1 
expression can cause tumor regression.
RSF-1 Promotes invasion in Xenograft Models
To further characterize the role of RSF-1 in breast cancer, we analyzed the TCGA gene 
expression data and identified gene-expression signatures associated with RSF-1 expression 
levels ((Akavia et al., 2010; Danussi et al., 2013), (Supplementary Methods). Genes 
associated with RSF-1 in this procedure are putative downstream targets of RSF-1 activity. 
We performed gene set enrichment in these signatures using the MSigDB database 
(Subramanian et al., 2005) and found enrichment for gene sets involved in invasion, 
metastasis, and de-differentiation (Figure 6A, Supplementary Figure 6A).
Therefore, we hypothesized that RSF-1 overexpression may promote metastatic potential in-
vivo. To test this, we performed intravenous tail injection of MCF-10A-TM cells expressing 
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a luciferase reporter into SCID mice. When cells are injected intravenously in the tail of 
recipient mice, the cells travel through the circulatory system and are deposited in the lungs, 
where the majority of the cells die due to the absence of a supportive microenvironment 
(Yang et al., 2012). Both control and RSF-1 overexpressing cells were rapidly cleared and 
no signal was detected one week after the injection. Importantly, after 7 weeks all the mice 
injected with cells overexpressing RSF-1 showed luciferase signal in the lungs indicating the 
formation of lung metastases while luciferase signal was never recovered in mice injected 
with control cells (Figure 6B). This demonstrates that RSF-1 over-expression promotes 
increased invasive capacity in the lungs and therefore a pro-metastatic state in breast cancer 
cells.
In summary, we have shown that over-expression of RSF-1 confers increased anchorage 
independent growth in vitro and promotes the formation of lung metastases in mouse 
models. Additionally, we have identified a transcriptional signature associated with RSF-1 
amplification in primary tumors that was enriched for genes related to metastasis and 
invasion. The identification of RSF-1 as an oncogene that increases metastasic potential 
provides an explanation for the steep mortality of a recently identified molecular subgroup 
of breast cancer al (Curtis et al., 2012).
Discussion
Cancer research has recently been driven by the hope that therapies targeting drivers will be 
especially effective in tumors harboring genetic alterations in the target. This approach relies 
on the oncogene addiction effect whereby cancer cells become dependent on the activity of 
their altered oncogenes, so that inhibiting them compromises cellular viability. This 
“personalized medicine” is the basis of some of the most effective therapies, e.g. those 
targeting ERBB2 amplification in breast cancer (Ashworth et al., 2011). The success of 
these therapies has fueled efforts to catalog the genomic alterations in numerous cancers 
with the hopes of discovering new therapeutically actionable mutations.
However, even as data from cancer genomes accumulates, the identification of actionable 
driver genes remains a crucial limitation to therapeutic development. We see at least two 
significant bottlenecks. First, only a small subset of established driver genes are druggable 
given the current pharmalogical state of the art (Collins and Workman, 2006). Second, even 
when a driver is druggable, it may occur in a very small fraction of patients, limiting its 
clinical utility. At present, there is an untapped resource of driver genes in SCNAs that have 
evaded discovery. Moreover, due to the high frequency of SCNA events, actionable drivers 
can impact more patients (Figure 1A). However, to date, this possibility has been crucially 
limited by the difficultly of distinguishing passengers and drivers in the majority of SCNAs.
Here, we have presented a major advance in addressing this challenge, using a method that 
integrates data from primary tumors with functional assays on cell lines to prioritize 
candidate drivers. The unparalleled sensitivity and specificity of Helios enabled us to 
execute the first reported systematic validation of an algorithm designed to identify tumor 
dependencies. Helios’s performance was confirmed by a success rate of 10/12 candidates in 
an anchorage independent growth assay, successfully characterizing several regions for 
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which there was no previously implicated driver. Importantly, because we selected the genes 
for validation based on their amplification significance (ISAR score), rather than their 
Helios score, we expect that this success rate will extend to additional regions that have 
equally strong Helios scores. Moreover, many of these genes are amplified in additional 
epithelial cancers (e.g. C6orf203, NIT1, ZNF652) suggesting possible drivers in those 
cancers as well.
Using Helios, we have significantly expanded the landscape of high-confidence breast 
cancer drivers by more than two fold (Figure 7 and Supplementary Figure 7). Previous 
analyses of breast cancer cohorts (Stephens et al., 2012; TCGA, 2012) had identified 15 
driver genes amplified in at least 5% of breast cancer tumors (both SCNA and sequence 
mutations). Our analysis has doubled this number to 29, substantially expanding the list of 
potential drug targets. Even more importantly, we have increased the number of drivers 
identified in each tumor, thus raising the possibility that at least one might be actionable in a 
given patient. A previous study (Figure 7B, grey boxes (Stephens et al., 2012)), could assign 
each tumor a median of 2 established drivers. Adding the Helios validated genes increases 
this number to a median of 3 drivers per tumor (Figure 7B, green boxes). Adding all 
predicted drivers with a high Helios score further expands this number to a median of 5 
drivers in each tumor (Figure 7B, yellow boxes). Thus Helios has substantially expanded the 
set of high-confidence drivers in breast cancer.
Helios uses a technique called transfer learning, whereby drivers with clearer signal (e.g. at 
the peak of their region) help learn informative features to improve performance in cases 
with less obvious signal. Helios learns the list of candidate drivers without using any prior 
list of driver genes and therefore it does not suffer from any bias that would hinder the 
discovery of novel biology. The algorithm uses all data in its learning process, transferring 
information across different genes, as well as between copy number and other features, until 
it converges into a final ranking of candidate driver genes. By leveraging information in this 
fashion, Helios is capable of learning how to weigh and combine features into a probabilistic 
score that represents the likelihood of the gene being the target of the recurrent alteration. 
This computational framework is independent of the features and tumor type and it can be 
applied to analyze additional cancers using a similar or even different set of features.
Genetic, genomic and functional data on cancers will continue to accumulate from large-
scale projects in the coming years (Cheung et al., 2011; TCGA, 2008). Such datasets 
continue to accelerate drug development and to yield deep insights into oncogenesis. 
However, they also create new analytical challenges such as the need to pinpoint the 
alterations that promote cancer. Helios can be viewed as an accurate in silico screen for 
drivers. As such, it can be applied to additional cancer types and data types to accelerate the 
identification of cancer drivers.
Experimental Methods ISAR
ISAR is based on the G-score metric, a significance measure of the aberration for each 
marker, which was originally defined in GISTIC (Beroukhim, Getz et al. 2007). 
Specifically, the G-score for a marker m is the summation of the copy number across 
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samples that surpass an aberration threshold θ. Given the copy number for N samples, the G-
score for a marker m in the case of amplifications is:
Eq. 1
Where CN(m,i) is the copy number of marker m in sample i and I is the indicator function. 
ISAR uses a local sliding window of constant size that moves along the chromosome, 
calculating the null distribution for each window. Once the distribution has been computed 
in all windows within a chromosome, each genomic marker is associated with several 
overlapping windows. The algorithm takes a conservative approach by selecting the least 
significant q-value among the values computed for all overlapping windows containing the 
marker (See Supplementary Methods for more detail).
Modeling copy number
We aim to model a distribution of SCNA that reflects the differences between driver and 
passenger genes, independently of the chromosomal region. However, in contrast to the 
subtle differences in SCNA within each altered region, the distribution of alterations differs 
dramatically between regions. Indeed, the median difference in G-score between genes in a 
region is significantly smaller (172) than the difference for genes across different regions 
(6405). Thus, without appropriate normalization, the G-score should not be used to prioritize 
drivers across regions. We aim to model whether the gene is among the most altered genes 
in its own region (and therefore more likely to be the driver of that region) and therefore 
define a metric that measures the difference in terms of G-score to the highest value in each 
region. For a single gene g, we define the GSDist score as:
Eq. 2
The most altered gene(s) in a region will have GSDist=0, while any other gene will have a 
positive value that indicates the “distance” to the most frequently amplified gene in the 
region. Note that traditional approaches would use a threshold on this metric to make a hard 
decision on whether genes in the altered region are peak genes (Figure 2B). Instead Helios 
models this metric using two exponential distributions (one for drivers and one for 
passengers):
Eq. 3
Driver genes have a GSDist distribution that exponentially decreases from zero with small 
variance, whereas passenger genes are modeled by a uniform distribution, which is 
approximated by an exponential distribution with large variance (See Supplementary 
Methods for more detail).
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Features used in the Helios algorithm
We use MutSig (Banerji, Cibulskis et al. 2012) to compute the statistical significance of the 
recurrence of point mutations.
Helios uses features extracted from RNA-Seq based gene expression in two different ways: 
(1) To identify genes that are not expressed and therefore unlikely to be drivers. (2) We 
expect the oncogenic activity of an amplified driver gene to be reflected in the gene’s 
mRNA dosage (Akavia et al., 2010).
The oncogene addiction score for a hairpin is defined as the log-likelihood of the monotonic 
regression that predicts the lethality based on the gene mRNA. We use the PAVA algorithm 
(Brunk, 1955) to estimate the best fit for the regression (See Supplementary Methods for 
more detail).
Helios Algorithm
Helios uses a hierarchical Bayesian mixture model to distinguish drivers from passengers 
among the genes present in significantly altered regions. The unsupervised Bayesian 
algorithm discriminates driver genes (T=1) by integrating the copy number alteration 
information (SCNA), with cues from different data sources (X). The hierarchical framework 
naturally separates these two components using the following model:
Eq. 4
This model separates the modeling of copy number (P(SCNA|T=t)) from other sources of 
information (P(T=t|X)), focusing on predicting the observed copy number landscape 
(P(SCNA)). The algorithm iteratively fits a model for each part: P(SCNA|T=t) and P(T=t|X) 
and updates the estimations for each gene (T) taking both parts into account. The algorithm 
is executed until the model converges into a stable solution that incorporates all the 
information into a single probability score for each gene.
Figure S2A shows the graphical model for Helios, where N genes are classified by 
combining the information from different data sources X and SCNA. w represents the 
parameters that control the integration of X, while λ parameterizes the influence of SCNA. 
In this model, when the values Tn for the genes are given, the parameters for the different 
sources (W) and copy number (λ) are independent. This property makes it possible to fit the 
model efficiently using the Expectation Maximization (EM) algorithm (See Supplementary 
Methods for more details).
Data Sets Used for Helios
We used the following public datasets:
• Primary tumor data from the TCGA Project (TCGA 2012): copy number 
Affymetrix 6.0 SNP arrays (n=785), Illumina HiSeq RNA sequencing (n=732) and 
whole-exome sequencing (n=507).
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• Cell line shRNA screens (n=29) collected by Marcotte et al. (Marcotte, Brown et 
al. 2012).
• Cell line data from the Cancer Cell Line Encyclopedia (Barretina, Caponigro et al. 
2012) for the cell lines screened with shRNA: copy number Affymetrix 6.0 SNP 
arrays (n=27) and messenger RNA Affymetrix U133 plus 2.0 arrays (n=27)
Data Sets Used to generate Gold Standard Set
To assess performance, a gold standard set of 330 genes was compiled from the following 
sources:
• The set of known amplified oncogenes from Beroukhim et al. (Beroukhim, Mermel 
et al. 2010)
• The set of genes related to Breast cancer according to the University of 
Copenhagen DISEASES database (Frankild and Jensen) with score greater than 
2.5. We filtered out genes categorized as tumor suppressors according to Uniprot.
See supplementary Methods for more information
Cell culture and reagents
To generate cell lines overexpressing a gene, cells were plated at 60% of confluence in a 6 
well plate and after 24 hours infected with virus expressing the different plasmids containing 
the different genes. Media containing virus was replaced in 12h for fresh media. After that 
cells were re-infected for other 12h. Cells were grown in fresh media for 24h and selected 
with the appropriate drug. Alternatively, to generate MDA-MB 453 deficient in RSF1, cells 
where infected with virus expressing doxycycline-inducibles pTRIPz shRNA against RSF1 
and selected with the puromycin (2ug/mL).
See Supplementary methods for Cell lines, DNA constructs and gene cloning strategy.
Validation of Helios predictions was based on the ability of MCF-10A to form colonies in 
semi-solid media when the putative oncogene was experimentally upregulated. Because low 
passage MCF-10A are very resistant to transformation, to increase the sensitivity of our 
assay, we selected a passage with intrinsic low attachment independent growth ability (5–15 
colonies per 5,000 plated cells) that demonstrated robust higher growth ability when bona-
fide breast oncogenes were overexpressed (Supplementary Figure 4A).
Colony formation assay in semisolid media was performed in 6 well plates. First, a layer of 
2 mls of 0.6% agar (Fisher #9002-18-0) in regular MCF-10A media was placed at the 
bottom of each well and allowed gelification. Then, layer of 2mls of 0.3% agar containing 
5,000 cells was seeded on top of the bottom agar layer and allow gelification. Finally, 1 ml 
of regular MCF-10A media was placed covering the agar. The colonies were allowed to 
form for 1 month. After this period 2 mls of MTT solution (Sigma #M5655) at 0.5mgr/ml 
was used to stain the colonies. A minimum of 6 replicas per gene were plated. To ensure 
comparability, transformation assays for each gene are compared to empty-vector controls 
performed together on the same day. The number of colonies was independently evaluated 
by two researchers. All the different MCF-10A clones carrying controls and genes of 
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interest were maintained growing exponentially for 48 hours (plates were at 50–70 
confluency) before being plated in agar to homogenize assay conditions.
Tumorigenicity in mice
Animal maintenance and experiments were performed in accordance with the animal care 
guidelines and protocols approved by Columbia University animal care unit. For 
Comma-1D cell line, 21 days old female NOD SCID immunocompromised mice 
NOD.CB17-Prkdcs SCID mice (Harlan) mice were injected with 5×105 cells, resuspended 
in PBS, into a fat mammary gland. For MDA-453 cell line, eight-weeks old female NOD 
SCID immunocompromised mice NOD.CB17-Prkdcs SCID mice (Harlan) mice where 
injected with 5×106 cells, resuspended in 1:2 Matrigel (BD Biosciences) plus normal growth 
media, into a fat pad mammary gland. Doxicyclin was added to drinking water at a final 
concentration of 2.0 mg/mL. Tumor growth was monitored twice a week with callipers at 
the site of injection. Animals were sacrificed as soon as tumor size reached 1.5 cm diameter.
In the experimental metastasis assays, eight-weeks old female NOD SCID 
immunocompromised NOD.CB17-Prkdcs SCID mice (Harlan) where injected with 5×106 
cells, resuspended in PBS, via the tail vein. To measure the luciferase intensity of injected 
cells, 2.25 ug ml-1 luciferin was injected intravenously through the tail and luciferase 
activity was assessed 5 minutes after luciferin injection using a IVIS Spectrum Pre-clinical 
in vivo Imaging System (PerkinElmer, IVISSPE) machine. The presence of established 
metastases was confirmed by euthanizing the mice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Helios integrates data from primary tumor and functional screens
(A) Frequency of alteration in the TCGA breast cancer dataset of (top) genes with recurrent 
point mutations and (bottom) regions of recurrent copy number alteration. Significant genes 
and regions were downloaded from the DBroad Genome Data Analysis Center, selecting the 
TCGA pipeline algorithms GISTIC2 (v. 4.2012021700.0.0) and MutSig (v. 
4.2011112800.0.0) (B) A schematic of our pipeline for the identification of candidate driver 
genes. The method first uses ISAR to identify regions of focal SCNAs. To pinpoint drivers 
within those regions, it extracts features from genetic, genomic and functional data, which 
are integrated into a single probabilistic score by Helios.
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Figure 2. Helios features
(A) Diagram of the classic and Helios approach. While the classic approach relies solely on 
copy number, both to identify significantly altered regions and to further narrow down those 
region to a minimal region of maximal alteration, Helios identifies regions in the same 
fashion, but then integrates features extracted from different data sources to compute the 
probability of each gene being a target of the region. (B) Diagram of the copy number model 
of the Helios Algorithm. The classic approach (top) calculate a hard threshold on the delta to 
the most altered marker (GSDist, X axis) to define the peak region (Y axis). Helios (bottom) 
instead calculates the probability (Y axis) of displaying a GSDist value (X axis) for both 
driver and passenger genes (yellow or brown curves respectively). (C) Our oncogene 
addiction score uses monotonic regression to measure the association between gene dosage 
(X axis) and shRNA dropout (Y axis), aiming to differentiate the proto-ongonenic state (I) 
of the driver, which is expressed at wild type levels, and the oncogenic state (II), which is 
characterized by high expression and high dependency on the gene for survival. (D) 
Monotonic regression of the shRNA dropout (Y axis) based on the gene dosage (X axis) for 
the two top scoring genes for oncogene addiction in the 17q12 region. (E) Monotonic 
regression of the shRNA dropout (Y axis) based on the gene dosage (X axis) for the two top 
scoring genes for oncogene addiction in the 14q13 region.
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Figure 3. Helios analysis of Breast Cancer
(A) A comparison of enrichment for a literature- compiled set of breast cancer drivers 
between our Helios genes defined as the top gene in each region with a score greater than 
0.5) and three state of the art methods. (B),(C),(D) and (E) display the result of the Helios 
analysis for the 12p14, 18q21, 1q21 and 7p12 regions respectively. Genes in the ISAR 
regions are displayed in the X axis and the Helios score is represented by bars colored 
proportionally to the contribution of each feature (a logistic regression approximation is 
employed to approximate the contribution of each feature). The ISAR score is displayed as a 
black line. (F) A comparison between Helios and the results from the analysis of the data 
sources individually, testing for enrichment based on our literature compiled set of breast 
cancer drivers. See Supplementary Figure 3A–D for information about convergence and 
stability of the results.
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Figure 4. Helios validations
Results of the systematic in-vitro validation of Helios candidates including the selected 
genes and 5 genes selected as negative controls (highlighted in grey). The ‘Ratio Next’ 
column indicates the ratio between the Helios score of the candidate gene and the score of 
the next best scoring gene in the region. The ‘Validation p-value’ displays the statistical 
significance of the change in colony size between the 6 empty vector controls and the 6 
repeats of the cDNA overexpressing the candidate driver gene. This p-value was computed 
using a right-tailed unpaired two-sample t-test. The ‘Supported Driver’ column indicates if 
the gene has been positively validated by the in-vitro assay or a known driver based on 
previous literature. The rightmost panel shows the box plots of the colony numbers for each 
gene in the validation experiment, where grey indicates the control and green the cDNA 
overexpressing the candidate driver gene. The colony assay was not performed for several 
genes that we failed to clone (MYO18A, SKI), or were bona fide drivers at the top of their 
peak (ERBB2, ZNF217, FGFR2, ANKRD17, IGF1R). Additionally, no gene scored above 
0.3 in the 17q23 region, suggesting that the target was another regulatory element, in this 
case the bona fide onco-microRNA MIR21. The three green boxes highlight amplified 
regions in which we confirmed more than one driver. The colony data that supports this 
figure is available in Supplementary Figures 4B (candidate drivers) and 4C (negative 
controls).
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Figure 5. High expression levels of RSF-1 promote tumorigenesis
(A) Overexpression of RSF-1 in multiple cell lines enhances its ability to form colonies in 
agar. (B) downregulation of RSF-1 using dox inducible shRNAs in a cell line with 
amplification of the locus (MDA-MB-453) reduced its ability to form colonies in agar. 
Overexpression of RSF-1 in (C) MCF-10A-TM and (D) CID cells enhanced their 
tumorigenic potential in vivo. The MCF-10A-TM model generated small tumor masses, thus 
H&E images are also provided. Number of tumors formed for each model is available in 
Supplementary Figure 5B. (E) Silencing of RSF-1 in MDA-MB-453 attenuated its 
tumorigenic potential when orthotopically transplanted in SCID mice.
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Figure 6. RSF-1 alteration promotes metastasis
(A) The analysis of the expression changes related to RSF-1 overexpression in basal primary 
tumors revealed a signature enriched for invasiveness, migration and dedifferentiation (table 
at right). The heat map at left shows genes in the signature as rows and samples as columns 
and the color indicates the relative expression (green-low and red-high) and demonstrates 
the tight correlation of the signature genes across patients. Similar results were observed for 
luminal primary tumors (Supplementary Figure 6A). See Supplementary Figure 6B-C for 
analysis of downregulated genes. (B) Comparison of lung metastasis formation in SCID 
mice subjected to tail vein injection of MCF-10A-TM cells expressing a luciferase reporter 
and either an RSF-1 over-expression vector or a control vector. H&E of sectioned lungs 
from mice injected with control and RSF-1 overexpressing cells is also shown. The arrows 
indicate the presence of metastatic outgrowths in the lungs.
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Figure 7. The landscape of driver mutations in breast cancer
For the driver genes described in (Stephens et al., 2012) (grey), Helios validated genes 
(green) and other Helios genes scoring > 5.5 (yellow) we compute (A) the number of tumors 
altered (copy number or sequence mutation) for each driver gene and (B) the number of 
driver genes altered (copy number or sequence mutation) per tumor. For this Figure we 
consider the 485 primary tumors in TCGA for which both copy number and DNA-Seq were 
available.
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